Hemagglutinin 5 (H5) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hemagglutinin 5 (H5) – Pipeline Review, H2 2016’, provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics.

The report provides comprehensive information on the Hemagglutinin 5 (H5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5)

The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects

The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Altravax Inc

Ilyang Pharmaceutical Co Ltd

Inovio Pharmaceuticals Inc

NewLink Genetics Corp

Vaxine Pty Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hemagglutinin 5 (H5) Overview 6

Therapeutics Development 7

Hemagglutinin 5 (H5) - Products under Development by Stage of Development 7

Hemagglutinin 5 (H5) - Products under Development by Therapy Area 8

Hemagglutinin 5 (H5) - Products under Development by Indication 9

Hemagglutinin 5 (H5) - Pipeline Products Glance 10

Early Stage Products 10

Hemagglutinin 5 (H5) - Products under Development by Companies 11

Hemagglutinin 5 (H5) - Therapeutics Assessment 13

Assessment by Monotherapy/Combination Products 13

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development 19

Altravax Inc 19

Ilyang Pharmaceutical Co Ltd 20

Inovio Pharmaceuticals Inc 21

NewLink Genetics Corp 22

Vaxine Pty Ltd 23

Hemagglutinin 5 (H5) - Drug Profiles 24

DPC-005 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

influenza [strain A/H5N1] vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

influenza [strain A/H5N1] vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

influenza vaccine 2 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

INO-3510 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

IY-7640 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

VGX-3400X - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Hemagglutinin 5 (H5) - Dormant Projects 33

Hemagglutinin 5 (H5) - Featured News & Press Releases 34

Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine 34

Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial 35

May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 36

May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 38

Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine 39

Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies 40

Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial 41

Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine 43

Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial 44

Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines 45

Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award 45

Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial 46

Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine 47

Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 47

Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Action, H2 2016 14

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Altravax Inc, H2 2016 19

Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2016 20

Pipeline by Inovio Pharmaceuticals Inc, H2 2016 21

Pipeline by NewLink Genetics Corp, H2 2016 22

Pipeline by Vaxine Pty Ltd, H2 2016 23

Dormant Projects, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Routes of Administration, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 15

Number of Products by Molecule Types, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports